Zealand Pharma: rescue pen proves effective in study
(CercleFinance.com) - A rescue pen being developed by Zealand Pharma led to improvement in readings of severe hypoglycemia, according to results of a late-stage clinical trial presented on Tuesday.
The Copenhagen-based biotech company said that, in a pivotal Phase 3 trial with dasiglucagon for severe hypoglycemia in diabetes, 99% of subjects recovered within 15 minutes following dosing with dasiglucagon, versus 2% with placebo and 95% with Novo Nordisk's GlucaGen.
Results also show that the median time to blood glucose recovery was 10 minutes for dasiglucagon, which was superior to placebo (40 minutes). By comparison, the median time to recovery for GlucaGen was 12 minutes.
Zealand Pharma shares were trading 8.4% higher on the Nasdaq Nordic market after these results were announced.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The Copenhagen-based biotech company said that, in a pivotal Phase 3 trial with dasiglucagon for severe hypoglycemia in diabetes, 99% of subjects recovered within 15 minutes following dosing with dasiglucagon, versus 2% with placebo and 95% with Novo Nordisk's GlucaGen.
Results also show that the median time to blood glucose recovery was 10 minutes for dasiglucagon, which was superior to placebo (40 minutes). By comparison, the median time to recovery for GlucaGen was 12 minutes.
Zealand Pharma shares were trading 8.4% higher on the Nasdaq Nordic market after these results were announced.
Copyright (c) 2018 CercleFinance.com. All rights reserved.